ClinicalTrials.gg
RecruitingNCT07067463Updated Nov 10, 2026

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

A Phase 3 interventional study of Orelabrutinib and Placebo in Multiple Sclerosis (MS) Primary Progressive, sponsored by Zenas BioPharma (USA), LLC. Recruiting at 86 sites in 18 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Zenas BioPharma (USA), LLC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 10, 2026First sites in Australia and Canada32 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
705
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States — 25 open to participants now, 38 under way, 9 of them phase 3. Multiple Sclerosis, Chronic Progressive · United States.

Planned enrollment
14th of 85
705 · median 59
Started
2026
with 8 others
Phase 3
20 of 105
4 open now
Primary completion
2030-06
later than 32 of 37 live
Registered
90th of 105
by date

Among the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, this one is the 14th largest by planned enrollment of the 85 interventional ones that give a count, is one of 9 that started in 2026, is one of 20 in phase 3, reaches primary completion later than 32 of the 37 other live ones, and was the 90th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

25 of the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, or all of them as a file.
02

Study summary

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for approximately 30 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 705 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

03

Conditions studied

  • Multiple Sclerosis (MS) Primary Progressive
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 60 years of age, inclusive
  • Diagnosed with Primary Progressive MS (PPMS) according to 2017 McDonald criteria
  • Participant must have documented evidence of disability progression observed during the 24 months before screening.
  • Expanded disability status scale (EDSS) score between 3.0 to 6.5 points, inclusive, at Screening.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)
  • Immunologic disorder other than MS or any other conditions requiring oral, intravenous (IV), intramuscular, or intra-articular therapy.
  • History or current diagnosis of other neurological disorders that may mimic MS
  • History of any other significant active medical condition
  • History of suicidal behavior within 6 months prior to Screening
  • Any prior history of if no recurrence within 5 years
  • Patients on anticoagulation, or antiplatelet therapy will be excluded
  • Patients took strong/moderate inhibitors or strong/moderate CYP3A inducerswithin 14 days
  • laboratory abnormalities at Screening.
  • Any allergy, , or inability to tolerate orelabrutinib or any of the in the study intervention
  • Vaccination with live or within 1 month prior to Screening
  • History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
705 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib Group

    Drug: Orelabrutinib

  • Placebo comparator
    Placebo Group

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to onset of composite confirmed disability progression (cCDP) , confirmed over at least 12 weeks (12-week cCDP)

    * Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is \> 5.0, OR * ≥ 20% increase in the Timed 25-Foot Walk Test (T25FWT), OR * ≥ 20% increase in the 9-hole Peg Test (9HPT)

    Time frame: Up to approximately 120 weeks

Secondary outcomes

  1. Time to onset of composite confirmed disability progression (cCDP) , confirmed over at least 24 weeks (24-week cCDP)

    Time frame: Up to approximately 120 weeks

  2. Time to onset of confirmed disability progression (CDP) , confirmed over at least 24 weeks (24-week CDP)

    Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is \> 5.0.

    Time frame: Up to approximately 120 weeks

  3. MRI T2 lesion

    The total number of new/enlarging T2 lesions on MRI scans of the brain from baseline to Week 120

    Time frame: Up to approximately 120 weeks

  4. 12-week CDP

    Time to onset of CDP, confirmed over at least 12 weeks

    Time frame: Up to approximately 120 weeks

  5. Time to onset of CDP defined as ≥ 20% increase on 9-hole Peg Test (9HPT) from baseline, confirmed over at least 12 weeks (12-week CDP-9HPT)

    Time frame: Up to approximately 120 weeks

  6. Time to onset of CDP defined as ≥ 20% increase on Timed 25-Foot Walk Test (T25FWT) from baseline, confirmed over at least 12 weeks (12-week CDP-T25FWT)

    Time frame: Up to approximately 120 weeks

  7. 24-week cCDI

    Time to onset of composite confirmed disability improvement (cCDI) events, confirmed over at least 24 weeks

    Time frame: Up to approximately 120 weeks

  8. 24-week CDI-9HPT

    Time to onset of CDI on 9HPT defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks

    Time frame: Up to approximately 120 weeks

  9. 24-week CDI

    Time to onset of CDI on EDSS confirmed over at least 24 weeks

    Time frame: Up to approximately 120 weeks

  10. 24-week CDI-T25FWT

    Time to onset of CDI on T25FWT defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks

    Time frame: Up to approximately 120 weeks

  11. SDMT

    The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT)

    Time frame: Up to approximately 120 weeks

  12. AEs

    Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0); vital signs; electrocardiograms (ECGs); and clinical laboratory safety parameter

    Time frame: Up to approximately 120 weeks

07

Study locations

86 of 86 sites recruiting
08

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 51 months after the start.

Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's planned 51 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 16, 2025
StartActual
Mar 23, 2026
Primary completionEst.
Jun 2030
CompletionEst.
Jul 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
32 sites added, 11 sites removed — first sites in Australia and Canada
Show 32 added (6 Ukraine, 5 Italy, 5 Bulgaria, 4 Poland, 3 United States, 2 Romania, 1 Georgia, 1 Spain, 1 Australia, 1 Germany, 1 Serbia, 1 Slovakia, 1 Canada)
  • University G. D'Annunzio of Chieti-Pescara · Chieti, Italy
  • Limited Liability Company Medical Center Neuroclinic · Lviv, Ukraine
  • Medical Center Medica Plus OOD · Veliko Tarnovo, Bulgaria
  • Neurological Services of Orlando · Orlando, United States
  • MTZ Clinical Researcz Powered by pratia · Warsaw, Poland
  • CNE City Clinical Hospital #1 of Ivano-Frankivsk council · Ivano-Frankivsk, Ukraine
  • UMHAT Dr Georgi Stranski · Pleven, Bulgaria
  • LTD Pineo Medical Ecosystem · Tbilisi, Georgia
  • ARNAS Ospedali Civico Di Cristina · Palermo, Italy
  • Hospital Gregorio Marañon · Madrid, Spain
  • Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital · Chernivtsi, Ukraine
  • The Ohio State University Wexner Medical Center (OSUWMC) · Columbus, United States
  • Texas Institute for Neurological Disorders - Sherman · Sherman, United States
  • Neurology Network · Melbourne, Australia
  • UMHAT Dr Georgi Stranski · Pleven, Bulgaria
  • Medical Center Medica Plus OOD · Veliko Tarnovo, Bulgaria
  • DCC Neoclinic - Sofia · Sofia, Bulgaria
  • Zentrum fur klinische Forschung Dr.Scholl GmbH · Bad Homburg, Germany
  • Az. Osp.Universitaria Policlinico Federico II Centro Sclerosi Multipla Dip. Scienze Neurologiche · Naples, Italy
  • ARNAS Ospedali Civico Di Cristina · Palermo, Italy
  • Universita degli Studi di Torino - Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Clinica di Malattie dell'Apparato Respiratorio Neurologia & CRESM · Orbassano, Italy
  • Malva Trials · Lublin, Poland
  • Twoja Przychodnia Centrum Medyczne Nowa Sol · Nowa Sól, Poland
  • Centrum Medyczne Pratia Katowice · Katowice, Poland
  • Clinical Hospital of Psychiatry and Neurology · Brasov, Romania
  • Spitalul Clinic Judetean Mures · Târgu Mureş, Romania
  • Clinical Centre Kragujevac, Neurology clinic · Kragujevac, Serbia
  • Mudr. Beata Dupejova, neurologická ambulancia S.R.O. · Banská Bystrica, Slovakia
  • Medical Clinical Investigational Center of Medical Center LLC Health Clinic · Vinnytsia, Ukraine
  • UBC Hospital, University Of British Columbia · Vancouver, Canada
  • …and 2 more on the registry record
Show 11 removed
  • The Ohio State University Wexner Medical Center (OSUWMC) L3-100 · Columbus, United States
  • Texas Institute for Neurological Disorders · Sherman, United States
  • UMHAT Dr Georgi Stranski · Pleven, Bulgaria
  • Medical Center Medica Plus OOD · Veliko Tarnovo, Bulgaria
  • ARNAS Ospedali Civico Di Cristina · Palermo, Italy
  • Centrum Medyczne Pratia Katowice · Katowice, Poland
  • Malva Trials · Lublin, Poland
  • Twoja Przychodnia Centrum Medyczne Nowa Sol · Nowa Sól, Poland
  • Spitalul Clinic Judetean Mures · Târgu Mureş, Romania
  • Clinical Centre Kragujevac, Neurology clinic · Kragujevac, Serbia
  • Mudr. Beata Dupejova, neurologická ambulancia S.R.O. · Banská Bystrica, Slovakia
across 6 updates, Oct 5, 2026 – Nov 10, 2026
Show all 6 updates
  1. Nov 10, 2026
    3 sites added — first site in Canada
    Show 3 added (2 Ukraine, 1 Canada)
    • UBC Hospital, University Of British Columbia · Vancouver, Canada
    • Neuro Global · Ivano-Frankivsk, Ukraine
    • Lviv National Medical University named after Danylo Galytskiy · Lviv, Ukraine
  2. Nov 3, 2026
    18 sites added, 11 sites removed — first site in Australia
    Show 18 added (3 Bulgaria, 3 Italy, 3 Poland, 2 United States, 2 Romania, 1 Australia, 1 Germany, 1 Serbia, 1 Slovakia, 1 Ukraine)
    • The Ohio State University Wexner Medical Center (OSUWMC) · Columbus, United States
    • Texas Institute for Neurological Disorders - Sherman · Sherman, United States
    • Neurology Network · Melbourne, Australia
    • UMHAT Dr Georgi Stranski · Pleven, Bulgaria
    • Medical Center Medica Plus OOD · Veliko Tarnovo, Bulgaria
    • DCC Neoclinic - Sofia · Sofia, Bulgaria
    • Zentrum fur klinische Forschung Dr.Scholl GmbH · Bad Homburg, Germany
    • Az. Osp.Universitaria Policlinico Federico II Centro Sclerosi Multipla Dip. Scienze Neurologiche · Naples, Italy
    • ARNAS Ospedali Civico Di Cristina · Palermo, Italy
    • Universita degli Studi di Torino - Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Clinica di Malattie dell'Apparato Respiratorio Neurologia & CRESM · Orbassano, Italy
    • Malva Trials · Lublin, Poland
    • Twoja Przychodnia Centrum Medyczne Nowa Sol · Nowa Sól, Poland
    • Centrum Medyczne Pratia Katowice · Katowice, Poland
    • Clinical Hospital of Psychiatry and Neurology · Brasov, Romania
    • Spitalul Clinic Judetean Mures · Târgu Mureş, Romania
    • Clinical Centre Kragujevac, Neurology clinic · Kragujevac, Serbia
    • Mudr. Beata Dupejova, neurologická ambulancia S.R.O. · Banská Bystrica, Slovakia
    • Medical Clinical Investigational Center of Medical Center LLC Health Clinic · Vinnytsia, Ukraine
    Show 11 removed
    • The Ohio State University Wexner Medical Center (OSUWMC) L3-100 · Columbus, United States
    • Texas Institute for Neurological Disorders · Sherman, United States
    • UMHAT Dr Georgi Stranski · Pleven, Bulgaria
    • Medical Center Medica Plus OOD · Veliko Tarnovo, Bulgaria
    • ARNAS Ospedali Civico Di Cristina · Palermo, Italy
    • Centrum Medyczne Pratia Katowice · Katowice, Poland
    • Malva Trials · Lublin, Poland
    • Twoja Przychodnia Centrum Medyczne Nowa Sol · Nowa Sól, Poland
    • Spitalul Clinic Judetean Mures · Târgu Mureş, Romania
    • Clinical Centre Kragujevac, Neurology clinic · Kragujevac, Serbia
    • Mudr. Beata Dupejova, neurologická ambulancia S.R.O. · Banská Bystrica, Slovakia
  3. Oct 27, 2026
    5 sites added
    Show 5 added (1 Bulgaria, 1 Georgia, 1 Italy, 1 Spain, 1 Ukraine)
    • UMHAT Dr Georgi Stranski · Pleven, Bulgaria
    • LTD Pineo Medical Ecosystem · Tbilisi, Georgia
    • ARNAS Ospedali Civico Di Cristina · Palermo, Italy
    • Hospital Gregorio Marañon · Madrid, Spain
    • Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital · Chernivtsi, Ukraine
  4. Oct 20, 2026
    3 sites added
    Show 3 added (1 United States, 1 Poland, 1 Ukraine)
    • Neurological Services of Orlando · Orlando, United States
    • MTZ Clinical Researcz Powered by pratia · Warsaw, Poland
    • CNE City Clinical Hospital #1 of Ivano-Frankivsk council · Ivano-Frankivsk, Ukraine
  5. Oct 13, 2026
    1 site added
    Show site
    • Medical Center Medica Plus OOD · Veliko Tarnovo, Bulgaria
  6. Oct 5, 2026
    2 sites added
    Show 2 added (1 Italy, 1 Ukraine)
    • University G. D'Annunzio of Chieti-Pescara · Chieti, Italy
    • Limited Liability Company Medical Center Neuroclinic · Lviv, Ukraine
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07067463
Lead sponsor
Zenas BioPharma (USA), LLC
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Mar 23, 2026
Primary completion
Jun 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Patient and Medical Information
Contact
clinicaltrialsinfo@zenasbio.com
833-269-4696

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion